Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis.

@article{Badger2000DiseasemodifyingAO,
  title={Disease-modifying activity of SB 242235, a selective inhibitor of p38 mitogen-activated protein kinase, in rat adjuvant-induced arthritis.},
  author={Alison M. Badger and Don E. Griswold and Rasesh Kapadia and Simon M Blake and Barbara A. Swift and Sandra J. Hoffman and George B Stroup and Elizabeth Webb and David J Rieman and Maxine Gowen and Jeffrey C Boehm and Jerry L. Adams and Jessica C Lee},
  journal={Arthritis and rheumatism},
  year={2000},
  volume={43 1},
  pages={175-83}
}
OBJECTIVE To evaluate the effects of SB 242235, a potent and selective inhibitor of p38 mitogen-activated protein (MAP) kinase, on joint integrity in rats with adjuvant-induced arthritis (AIA). METHODS Male Lewis rats with AIA were orally treated either prophylactically (days 0-20) or therapeutically (days 10-20) with SB 242235. Efficacy was determined by… CONTINUE READING